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Summary
Background Advances in SARS-CoV-2 sequencing have enabled identification of new variants, tracking of its evolution, 
and monitoring of its spread. We aimed to use whole genome sequencing to describe the molecular epidemiology of 
the SARS-CoV-2 outbreak and to inform the implementation of effective public health interventions for control in 
Zimbabwe.
Methods We performed a retrospective study of nasopharyngeal samples collected from nine laboratories in Zimbabwe 
between March 20 and Oct 16, 2020. Samples were taken as a result of quarantine procedures for international arrivals 
or to test for infection in people who were symptomatic or close contacts of positive cases. Samples that had a cycle 
threshold of less than 30 in the diagnostic PCR test were processed for sequencing. We began our analysis in July, 2020 
(120 days since the first case), with a follow-up in October, 2020 (at 210 days since the first case). The phylogenetic 
relationship of the genome sequences within Zimbabwe and global samples was established using maximum 
likelihood and Bayesian methods.
Findings Of 92 299 nasopharyngeal samples collected during the study period, 8099 were PCR-positive and 328 were 
available for sequencing, with 156 passing sequence quality control. 83 (53%) of 156 were from female participants. At 
least 26 independent introductions of SARS-CoV-2 into Zimbabwe in the first 210 days were associated with 12 global 
lineages. 151 (97%) of 156 had the Asp614Gly mutation in the spike protein. Most cases, 93 (60%), were imported 
from outside Zimbabwe. Community transmission was reported 6 days after the onset of the outbreak.
Interpretation Initial public health interventions delayed onset of SARS-CoV-2 community transmission after the 
introduction of the virus from international and regional migration in Zimbabwe. Global whole genome sequence 
data are essential to reveal major routes of spread and guide intervention strategies.
Funding WHO, Africa CDC, Biotechnology and Biological Sciences Research Council, Medical Research Council, 
National Institute for Health Research, and Genome Research Limited.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
SARS-CoV-2 is a novel coronavirus and the causative 
agent of COVID-19.1 It is an enveloped, non-segmented, 
positive sense RNA virus with a diameter of about 
65–125 nm. It has four main structural proteins, the 
most important being the spike glycoprotein.
The virus has spread to more than 220 countries, 
leading to more than 242 million confirmed infections, 
and more than 4·9 million deaths as of Oct 21, 2021, 
with daunting health and socioeconomic challenges.2 
Low-income and middle-income countries have faced 
particular challenges in controlling SARS-CoV-2 
infections and reducing mortality as a result of typically 
weak public health systems and large populations of 
susceptible people including those with tuberculosis, 
HIV, diabetes, hypertension, anaemia, or malnutrition.3
The first COVID-19 case in Africa was recorded 
in Egypt on Feb 14, 2020,4 and on Feb 27, 2020, the 
sub-Saharan African region recorded its first case in 
Nigeria. Further cases in sub-Saharan Africa were 
recorded in South Africa on March 5 and Zimbabwe on 
March 20, 2020.5 The initial cases identified in Africa 
were found to have been mostly introduced from Europe, 
the Middle East, and the USA.4,6,7 There is an urgent need 
to understand the epidemiology of SARS-CoV-2 in Africa, 
particularly pertaining to transmission and mutation 
capacity.8 The SARS-CoV-2 mutation rate is estimated to 
be approximately 2·5 single nucleotide polymorphisms 
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(SNPs) per month.9,10 Despite having inadequate 
health systems in some African countries, the number of 
reported cases in many African countries, specifically 
Zimbabwe, increased more slowly than predicted in the 
initial wave of infection.11
Following confirmation of the first case on 
March 20, 2020, Zimbabwe introduced stringent control 
measures on March 23, which included controlling travel, 
transportation, and public gatherings. The first death was 
confirmed on March 24. Due to the measures imposed in 
other countries, there was an influx of Zimbabwean 
residents returning home and a 21-day quarantine was 
imposed starting March 30. Zimbabwe took the initiative 
to sequence SARS-CoV-2 samples from individuals 
collected between March and October, 2020. In this study, 
we aimed to use the sequencing results to understand 
early domestic transmission of the virus in Zimbabwe, add 
context to the regional and global SARS-CoV-2 genome 
sequence data, and to evaluate the role of rapid whole 
genome sequencing for outbreak analysis in Zimbabwe.
Methods
Study design and data sources
We performed a retrospective study using routinely 
collected nasopharyngeal samples from Zimbabwe. 
Details of study design are provided in appendix 1 (p 2). 
COVID-19 testing information was obtained from the 
Ministry of Health and Child Care of Zimbabwe, 
Epidemiology and Disease Control Unit. All samples were 
from people present in Zimbabwe during the period of 
study and were sampled due to quarantine procedures, or 
to test for infection in people who were symptomatic and 
close contacts. Epidemiological data for each COVID-19 
case (ie, geographical origin, case classification [imported 
or domestic], date of isolation, and date of death, if 
applicable) was extracted from surveillance data sub mitted 
to the Epidemiology and Disease Control Unit. All data 
were de-identified and ethical approval was waived by the 
Medical Research Council of Zimbabwe as routinely 
collected surveillance data were used. No specific consent 
was required from the patients whose data were used in 
this analysis as the National Microbiology Reference 
Laboratory has authority to handle patient data for public 
health monitoring under section 46 (notifiable diseases) of 
the Zimbabwe Public Health Act.
Procedures
In the selection of samples for genomic evaluation, we 
used a conveniently selected sample of all those that were 
test-positive from eight of ten provinces (appendix 1 
pp 6–8) diagnosed during the study period that had a 
cycle threshold of less than 30 in the diagnostic PCR 
test12 were processed for sequencing. Demographic data 
(ie, age, gender, place of origin, and history of travel) 
associated with sequenced samples were analysed.
Genomic analysis
In the determination of SARS-CoV-2 genome sequences 
and sequence analysis, RNA samples for whole genome 
sequencing were processed and complementary DNA and 
multiplex PCR reactions were prepared following the 
ARTIC nCoV-2019 sequencing protocol version 2. Libraries 
Research in context
Evidence before this study
A narrative review of all the available literature showed that 
there was limited evidence of the epidemiology and genetic 
characteristics of SARS-CoV-2 in Africa. We searched PubMed 
Central, Embase, LILACS, Google Scholar, and the Cochrane 
Library for published literature from Jan 1, 2019, to 
Dec 31, 2020, using the search terms, “SARS Cov 2” OR 
“COVID-19” AND “Genomic Epidemiology” AND “Global” AND 
“Africa”. Full text articles and abstracts of SARS-CoV-2 genome 
epidemiology studies conducted between the search dates were 
included in the review. Earlier SARS-CoV-2 genomic studies 
were for diagnostic purposes and assessment of transmission. 
These earlier studies were limited to Asia, Europe, and the USA, 
with few reported from Africa and Zimbabwe. 
Added value of this study
Genome surveillance of SARS-CoV-2 for Zimbabwe revealed that 
the majority were of lineage B, 97%, with the remaining being of 
lineage A. International and regional migration was the 
predominant driver of SARS-CoV-2 transmission in Zimbabwe 
during the early phases of the pandemic, compared with local 
migration. Lineage B.1.1.111 was first identified in Zimbabwe 
and subsequently in two other countries in the region. This 
finding highlights the importance of strengthening pathogen 
genomic surveillance in countries with high migration levels to 
facilitate early detection of new variants. Potential changes in 
transmissibility and outcome of infection of new strains 
compared with the ancestor lineage are key to determining 
appropriate interventions.
Implications of the all the available evidence
As with other previously reported pandemic influenza diseases, 
COVID-19 was predominantly transmitted through global and 
local migration. The use of lockdown measures to control 
transmission coupled with increasing globalisation of economies 
will affect economic activities, with low-income and middle-
income countries worst affected due to less developed and 
diversified economies. Public health interventions are urgently 
needed to contain the pandemic before low-income countries 
like Zimbabwe are further impoverished. The inclusion of 
genomic evidence will further contextualise the pandemic 
regionally and globally, helping in the identification of new 
outbreaks through phylogenetic and phylogeographical analyses.
For the ARTIC nCoV-2019 
sequencing protocol see 
https://artic.network/ncov-2019
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were prepared for sequencing on the Illumina platform 
and sequenced as described previously and summarised in 
appendix 1 (p 3).13,14 SARS-CoV-2 sequence data generated 
in this study (appendix 1 pp 8–13) or global sequences 
generated previously (appendix 2) are freely available in 
the global initiative on sharing avian influenza data 
(GISAID) as reported previously.5 The raw reads were 
demultiplexed using bcl2fastq (version 2.20, Illumina) 
allowing for zero mismatches in the dual barcodes to 
produce FASTQ files. The reads were used to generate a 
consensus sequence as described in appendix 1 (p 3). A 
consensus sequence was defined as passing quality control 
if greater than 50% of the genome was covered by confident 
calls and if there was no evidence of contamination in 
the negative control. This proportion is regarded as the 
minimum amount of data to be phylogenetically useful. 
A confident call was defined as having at least ten times 
depth of coverage. If the coverage fell below these 
thresholds, the bases were represented with an N character 
(to symbolise that the nucleotide base at this position 
is unknown). Low quality variants were also masked 
with Ns. Lineages were assigned to each genome with 
Pangolin15 with manual refinement. Global sequences 
from GISAID (downloaded on June 4, 2021) closely related 
to those from Zimbabwe were included in the phylogenetic 
analysis. All sequences were aligned against the reference 
Wuhan Hu-1 (GenBank accession number MN908947.3), 
and both maximum likelihood trees and Bayesian 
divergence times were estimated. Ancestral genomes were 
inferred over nodes of interest by empirical Bayesian 
reconstruction as described in appendix 1 (p 4).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
Of the 92 299 nasopharyngeal samples collected during 
the study period, 8099 were PCR positive and 328 were 
available for sequencing, with 156 analysed after passing 
sequence quality control (figure 1). Samples were from 
eight provinces (including the metropolitan Harare and 
Bulawayo provinces). Of these, 83 (53%) were from 
female participants and 73 (47%) were from male 
participants, ranging in age from 7 months to 10 years 
(five [3%]), 11–20 years (seven [4%]), 21–30 years 
(45 [29%]), 31–40 years (48 [31%]), 41–50 years (26 [17%]), 
and older than 50 years (25 [16%]). 62 (40%) samples 
showed evidence of local transmission, 93 (60%) were 
imported cases, and there was no information available 
for one case (1%). Among the imported cases, 67 (72%) 
Figure 1: Study profile
92 299 nasopharyngeal samples were collected at nine laboratories 
in Zimbabwe from March 20 to Oct 16, 2020 
8099 samples with positive PCR test within the first 210 days 
since the first case (ie, March 20 to Oct 16, 2020) 
328 convenient samples available for sequencing
156 sequences with less than 50% unknown nucleotide base at 
designated position passed quality control and were 
analysed further
84 200 samples with negative PCR test 
7771 unavailable samples
172 samples with a cycle 
threshold of more than 30 or 
more than 50% unknown 
nucleotide base at 
designated position in 
sequence quality control 
Figure 2: Epidemic curve of SARS-CoV-2 confirmed cases as of Oct 16, 2020
(A) Cumulative number of positive tests for SARS-CoV-2 in individuals reporting 
travel in the previous 2 weeks (probable imported cases) or domestic cases by 
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of 93 were travellers from South Africa. Most cases were 
of the lineage B.1.1 (51 [33%]), B.1.1.111 (35 [22%]), or B.1 
(27 [17%]).
Most of the initial COVID-19 cases in Zimbabwe 
between March 20 and June 30, 2020, were Zimbabwean 
residents returning from neighbouring Botswana, 
Mozambique, and South Africa, the majority of whom 
were aged 25–45 years (Survellance data, Department of 
Epidemiology and Disease Control, Ministry of Health 
and Child Care, Zimbabwe, personal communication). 
The country recorded a case fatality rate of 2·9% (231 of 
8099) with those in the 31–40 year age group being most 
affected. The epidemiological curve plotted (figure 2A, B) 
was based on 8099 reported positive cases identified 
from the 92 299 national samples made available between 
March 20 (first case) and Oct 16, 2020. From the time 
the first case was recorded until 120 days later (ie, until 
July 18), more travel-associated cases than locally 
transmitted cases were detected. Most travel-related 
cases were asymptomatic (appendix 1 p 8). The number 
of cases with no reported history of travel in the previous 
2 weeks remained less than 50 during this period. People 
travelling from South Africa accounted for the greatest 
proportion (72 [72%] of 100) of travel-associated cases 
during the first 120 days. In late July, there was a rapid 
increase in the number of reported cases with no travel 
history, confirming the start of community transmission.
To place the genomes from Zimbabwe SARS-CoV-2 
samples into a global context, closely related genomes 
from abroad were analysed together, to produce a 
maximum likelihood phylogenetic tree of 472 genomes 
(figure 3). The 156 genomes from Zimbabwe could be 
placed within 12 previously defined global lineages 
(table). Four samples (3%), were from high-order 
Figure 3: Phylogenetic relationship of SARS-CoV-2 genomes from Zimbabwe and closely related genomes from global cases
Maximum likelihood phylogenetic tree of 156 SARS-CoV-2 genomes from Zimbabwe together with their closest 316 genomes from global samples. Lineages 
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lineage A, with the remaining genomes (n=152, 97%) 
derived from lineage B. The most common lineage, 
B.1.1, was first observed in April, 2020; table). Lineage 
B.1.1.111 was first observed in Zimbabwe, followed by a 
further eight sequences in Zambia and one in Kenya 
in June.
A maximum likelihood tree based on variation in 
the nucleotide sequence revealed a population structure 
for Zimbabwean cases of COVID-19 that grouped 
into 13 clusters. Each comprised multiple genomes 
that emerged from nodes distributed throughout the 
tree; 15 genomes were present as separate lineages 
(appendix 1 p 6). If each of these clusters represent 
separate introductions, we can infer that at least 
28 independent introductions took place for which there 
was good supporting evidence, as given by the existence 
of close genomes on GISAID from other countries 
separating the Zimbabwean clusters in the tree. 
However, in the case of four clusters or single genome 
lineages, the tree topology suggested that the genomes 
arose by divergence from just two introductions 
into Zimbabwe. In each case, two lineages shared a 
common ancestor with no intermediary nodes formed 
with genomes from other countries. By this more 
conservative estimation, the minimum number of 
introductions into Zimbabwe that our data support 
was 26. By reconstructing the ancestral locations on the 
Bayesian time tree, the number of transitions (from 
abroad to Zimbabwe) was estimated to be 29 (appendix 1 
p 6). The 13 clusters were each composed of between 
two and 30 genomes with 0–3 SNPs between members 
of the cluster. Seven clusters contained more than one 
genome that had an identical genome sequence to at 
least one genome in the same cluster.
Two large clusters within lineage B.1.1 were present on 
extended branches of the phylogenetic tree, composed of 
genomes that were distinct by 4–5 SNPs from all other 
sequences in the GISAID database. One of these clusters 
met all the requirements for a new lineage according 
to the PANGO classification (ie, well supported mono-
phyletic group, introduced and circulating in a new 
region, with defining SNPs). These defining features 
led to the designation of lineage B.1.1.111. The branch 
leading to this cluster was estimated to contain five 
SNPs, including the replacements Phe35Ser in open 
reading frame (ORF)10, Lys1895Asn in ORF1A, and 
Lys2557Arg in ORF1B. The other cluster consists of eight 
sequences from lineage B.1.1.459 (appendix 1 p 6). Using 
a Bayesian relaxed clock model, we estimated the time to 
the most recent common ancestor for each of these 
clusters to a few weeks before their sampling: beginning 
of April, 2020, for the B.1.1.111 cluster and mid-May for 
B.1.1.459 (appendix 1 p 6). These introductions into 
Zimbabwe might have been from geographical locations 
where the sequence of SARS-CoV-2 was not reported. 
The results could be caused by sequence divergence 
from an earlier case within the country not included in 
our analysis. Due to the sparse sampling due to 
incomplete surveillance, it is not possible to pinpoint 
the direction of transmission or to establish better 
phylogeographical estimates for this dataset. By super-
posing the ancestral shifts from abroad to Zimbabwe on 
the Bayesian time estimates of tree nodes, we inferred 
that most transmissions occurred between mid-February 
and mid-March, 2020  (appendix 1 p 6).
We established the distribution and frequency of the 
Asp614Gly variant in SARS-CoV-2 genomes from 
Zimbabwe. 151 (97%) of 156 samples contained the 
Asp614Gly mutation. Four of the five samples with the 
ancestral 614Gly were from a single cluster of identical 
genomes from lineage A, which was associated with 
travel from Dubai (United Arab Emirates); the other was 
from lineage B.39 and associated with travel from the 
USA. All five were from cases presenting in March or 
April, 2020.
Genomic epidemiology identified intercontinental 
transmission and local transmission in the first 210 days 
of the epidemic. National surveillance in Zimbabwe 
identified the first three cases of COVID-19 in the 
second half of March, 2020, in three individuals with a 
history of international travel within the previous 
2 weeks. These individuals had arrived from the UK, the 
USA, and Dubai and corresponded to samples ZW-25, 
ZW-29 and ZW-70, respectively (appendix 1 p 6). The 
genome sequence of samples ZW-25 and ZW-29 were 
identical, suggesting a recent common source or 
direct trans mission. These genomes together with a 
few others were classified as B.1.446, although other 
sequences in the same phylogenetic cluster did not have 
enough defining SNPs for a more specific PANGO 
classification. This mismatch between the PANGO 
classification and the phylogeny is due to the presence 
Zimbabwe (n=156) South Africa (n=3015) Global (n=299 405)
Number of 
samples
Percentage Number of 
samples
Percentage Number of 
samples
Percentage
B.1.1 51 32·7% 301 10·0% 32 163 10·7%
B.1.1.111 35 22·4% 0 0 27 <0·1%
B.1 27 17·3% 379 12·6% 57 071 19·1%
B.1.446 16 10·3% 0 0 237 <0·1%
B.1.1.459 8 5·1% 32 1·1% 32 <0·1%
B.1.1.57 5 3·2% 62 2·1% 67 <0·1%
A 4 2·6% 4 0·1% 2153 0·1%
B.1.381 4 2·6% 69 2·3% 69 <0·1%
B.1.1.200 3 1·9% 0 0 126 <0·1%
B.1.1.306 1 0·6% 0 0 1383 0·5%
B.1.1.62 1 0·6% 25 0·8% 26 <0·1%
B.39 1 0·6% 2 0·1% 412 0·1%
Data submitted to GISAID16 before Oct 16, 2020 (using PANGO lineages from GISAID June 4, 2021). GISAID=global 
initiative on sharing avian influenza data.
Table: Summary of lineages circulating in Zimbabwe, South Africa, and globally in the first 210 days of 
known cases
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of ambiguous bases in the genomic DNA, in particular 
N (ie, unknown nucleotide base at designated position. 
Pangolin thus conservatively classified them as B.1, a 
very common lineage in the GISAID database 
(figure 4).16 After visual inspection of the alignments and 
tree clustering, a correction of their classification was 
made.
Genome ZW-70 from a traveller arriving from Dubai 
was identical to three other genomes: ZW-168, ZW-169, 
and ZW-214. Dubai is an important hub for flights from 
many locations in the world including Asia. Local 
epidemiological investigation indicated that these were 
infections resulting from cohabitation and might 
represent the earliest cases of local transmission. This 
interpretation was supported by whole genome 
sequencing data. Genomes ZW-168, ZW-169, and ZW-214 
all belonged to lineage A, which is most widely distributed 
in China.
An additional eight genomes were associated with 
arrivals from the UK and three with arrivals from the USA 
in late March or April, 2020. International travel was 
suspended following the arrival of these cases. Nine of 
these 11 genomes belonged to the B.1 lineage, while one, 
from a case imported from the USA, belonged to the B.39 
lineage. Although in the same B.1 lineage, eight of these 
travel-associated cases were from different sublineages 
and, with one exception, had no identical genomes from 
non-travel associated COVID-19 cases in our dataset. The 
one exception was sample ZW-25BY, which was from a 
case recorded in Bulawayo in April, which was identical to 
samples ZW-391 and ZW-EC, also from Bulawayo, with no 
travel history recorded. This finding represents potential 
local transmission. Furthermore, they are phylogenetically 
very close to samples assigned to lineage B.1.446, and by 
visual inspection of the genomes, it was confirmed that 
they could not be classified with confidence by the 
software due to singletons or ambiguous bases (figure 4).
An increase in cases associated with Zimbabwean 
residents returning from neighbouring countries, 
especially South Africa, during May, 2020, was reported by 
local surveillance. As SARS-CoV-2 was reported to be 
spreading rapidly in South Africa at the time, a 2-week 
quarantine in accommodation designated by the Ministry 
of Health and Child Care was introduced. Although most 
returnees were asymptomatic, they were tested and 
on multiple occasions were positive for SARS-CoV-2. 
26 samples from quarantined individuals housed in 
six quarantine accommodation settings were sequenced. 
In several quarantine accommodation settings, genomes 
from multiple samples from different individuals resident 
in the same quarantine location were identical or differed 
by only a single nucleotide in the genome. For example, in 
quarantine location G (appendix 1 p 8), two clusters were 
identified that separately consisted of ten and 14 samples 
Figure 4: SNP differences between genomes from the cluster containing the B.1.446 lineage and the ancestral sequence
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(May, 2020). All of these were of the B.1.1 lineage with 
genomes that were indistinguishable from one another, 
consistent with direct transmission. Since returnees from 
multiple locations were quaran tined together, the most 
probable explanation is that transmission occurred in the 
quarantine facility rather than from a common outside 
source. Later spread was primarily linked to returnees 
from South Africa and potential transmission in 
quarantine facilities.
To investigate SARS-CoV-2 sequences associated with 
the first wave of the pandemic from July to October, 2020, 
we sequenced an additional 56 genomes from infections 
in this period. During this period, most infections were 
thought to result from domestic transmission rather 
than additional intro ductions from returning travellers. 
Consistent with this hypothesis, the vast majority of 
genomes were from the same lineages as those observed 
in the period in which transmission was mainly 
associated with imported cases in the first 120 days 
(appendix 1 p 6). The only exceptions to this pattern was 
a single lineage B.1.1.306 sample in July and four samples 
of lineage B.1.1.200 in October, which had not been 
sampled in the first 120 days.
Discussion
Epidemiological analysis identified two phases of the 
SARS-CoV-2 epidemic in Zimbabwe. Most cases in the 
first 90 days were associated with intercontinental or 
intracontinental travel. This finding was confirmed by 
the epidemiological data linking most confirmed cases 
with a history of travel outside of Zimbabwe, from 
international locations in which there were rising cases 
and local transmission. A smaller number of cases were 
imported from Asia, Europe, and the USA, the early 
epicentres of the SARS-CoV-2 epidemic.
For the first 120 days after the first case of COVID-19 
was identified in Zimbabwe, the total number of detected 
cases remained less than 50, suggesting that public 
health interventions were effective in limiting local 
transmission to a minimum. The rise in cases was slower 
than initially predicted and mirrored what was seen in 
many African countries.11 This slow rise in cases could be 
attributed to the measures the country instituted, which 
were shown to minimise and contain the outbreak in 
other countries, including France.17–20 Evidence suggests 
that quarantine of travel-associated cases and early 
suspension of tourism-associated travel might have been 
effective.
After July, 2020, a rapid increase in the number of cases 
was associated with probable domestic transmission, 
consisting predominantly of SARS-CoV-2 lineages 
present in the first 120 days that were imported into the 
country by travellers. Notably, no samples of lineage A 
were detected after March, 2020. The greatest number of 
cases centred around cities with close proximity to land 
borders or international airports and densely populated 
areas—namely Bulawayo, Gweru, and Harare. These 
factors might explain how the COVID-19 epidemic curve 
showed propagated transmission.
The case fatality rate of COVID-19 in Zimbabwe 
was 2·9%, which was similar to that reported elsewhere 
in Asia, Europe, and the USA. However, low access 
to testing in the community and health-care settings 
might have underestimated the true magnitude of the 
case fatality rate. This under-reporting was difficult to 
quantify.21–23 Compared with reports from other countries, 
younger men aged 31–40 years were the most likely to be 
infected with SARS-CoV-2 in Zimbabwe during the first 
120 days of the epidemic, but individuals older than 
60 years were more likely to die from COVID-19, as 
observed in other regions.24,25 The WHO report for the 
period of January to July, 2020, indicated that 64% of 
those infected were aged 25–64 years. However, older 
members of the population with pre-existing medical 
conditions were also at increased risk of dying after being 
diagnosed with COVID-19.26,27 In the UK, girls and 
women were significantly over-represented in the first 
wave of infection.28 The greater proportion of boys and 
men infected in Zimbabwe might reflect their prevalence 
in the mobile work force who move to other countries in 
search of employment.
14 of the 156 SARS-CoV-2 cases sequenced reported 
that the individual infected had travelled from outside 
the African region (ie, Dubai, the UK, and the USA). The 
sequences of SARS-CoV-2 genomes associated with 
travellers returning from neighbouring southern African 
countries were distinct from those associated with 
travellers from these three places, and recorded earlier in 
the epidemic. Among those returning from southern 
Africa, most were from lineage B.1.1, which was also the 
most common lineage among 2016 sequences from 
18 African countries reported by the WHO Regional 
Office for Africa. Lineages B.1.1.448 and C.1, which 
together accounted for 26% of the samples reported in 
South Africa before November, 2020, were not found in 
our analysis of samples from Zimbabwe.
There has been considerable interest in the 
emergence of a variant lineage of SARS-CoV-2 with a 
non-synonymous mutation resulting in substitution of 
614Gly in which a glycine residue was replaced by an 
aspartate residue at position 614 (Asp614Gly) of the spike 
protein. The spike protein is thought to be important for 
entry of the virus into host cells and Asp614Gly has been 
implicated in increased cell entry.29,30 Consistent with this 
idea, the 614Gly variant increased in frequency in the UK 
relative to the 614Asp ancestral variant, suggesting a 
selective advantage for 614Gly. The 614Gly genotype 
was the most frequent variant in early spread events 
in Zimbabwe, consistent with the reported trend for 
increased frequency of this genotype in many locations 
globally.29 The 614Asp genotype was found in just 
five samples from a single household-linked cluster of 
infections that occurred very early in the epidemic and 
were not found after this point. The dominance of the 
For the WHO Regional Office 
for Africa see 
https://www.afro.who.int/
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614Gly genotype in Zimbabwe probably reflects the high 
frequency of the 614Gly genotype in countries from 
which the virus was introduced. Although in the present 
work we cannot establish an increase in 614Gly infectivity, 
the notable absence of 614Asp, despite evidence of at 
least two introductions and household transmission, 
supports the fitness advantage of the 614Gly genotype.
We analysed data from most provinces in Zimbabwe; 
however, as convenience sampling was used, it is not 
clear whether this population is representative of the 
whole population. Also, as in all studies investigating 
COVID-19, the case burden will be underestimated 
as cases are only tested at prespecified intervals (in 
quarantine facilities) or for symptomatic cases meaning 
asymptomatic individuals are missed, thus under-
estimating case burden.
Our whole genome sequence analysis provides a 
baseline view of the SARS-CoV-2 lineages introduced 
into Zimbabwe, which will further inform analysis of 
later domestic spread of the virus. As the national 
response to the SARS-CoV-2 pandemic continues, the 
capability to test, isolate, and track the evolution of 
SARS-CoV-2 is crucial to assess ongoing mutation of the 
virus and inform public health measures to control the 
spread of this deadly disease.
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